title: Clinical pharmacology of antifungal agents in pediatrics: children are not small adults.
abstract: The optimal dosage information to improve the prognosis of invasive fungal infections in children and neonates is still limited and current dosing strategies are supported mainly by adult studies and extrapolation. Significant progress has been made to address this need in the last decade. Pre-clinical models and pharmacokinetic-pharmacodynamic (PK-PD) bridging studies supported by pediatric pharmacokinetic studies have investigated optimal dosing regimens for neonates and children. Here, we review the rationale for various antifungal regimens in infants and children.
authors.affiliation: Department of Molecular and Clinical Pharmacology, University of Liverpool, UK; Alder Hey NHS Children's Foundation Trust, UK.
authors.forename: Virginia
authors.initials: V
authors.lastname: Ramos-Martín
authors.affiliation: Alder Hey NHS Children's Foundation Trust, UK.
authors.forename: Olya
authors.initials: O
authors.lastname: O'Connor
authors.affiliation: Department of Molecular and Clinical Pharmacology, University of Liverpool, UK. Electronic address: william.hope@liverpool.ac.uk.
authors.forename: William
authors.initials: W
authors.lastname: Hope
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002648:Child; D054714:Echinocandins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D010372:Pediatrics; D010601:Pharmacology, Clinical; D011090:Polyenes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014230:Triazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D011090:Polyenes; D014230:Triazoles